American Association of Individual Investors3 天
Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Down 10.92%
TScan Therapeutics, Inc.’s TCRX share price has dipped by 10.92%, which has investors questioning if this is right time to buy.
来自MSN24 天
TSC President Inspects Special Forces
TSC President and Commander-in-Chief of the Armed ... MA/BH Provided by SyndiGate Media Inc. ( Syndigate.info ...
来自MSN1 个月
TSC President sends congratulatory cable to Syrian President on the occasion of assuming ...
TSC President referred to the distinguished bilateral ... BH/BH Provided by SyndiGate Media Inc. ( Syndigate.info ...
Cassava: Low-Cost Pivot Into TSC Epilepsy Is Unlikely To Create Long-Term Value
Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead to shareholder dilution. Learn more on SAVA stock here.
Cassava Sciences, Inc.: Cassava Sciences Reports 2024 Financial Results and Provides ...
ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic ...